News Conference News ESC 2025 ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients Michael O'Riordan September 10, 2025
News Conference News ESC 2025 Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b Caitlin E. Cox August 31, 2025
News Conference News ESC 2024 Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events Michael O'Riordan September 01, 2024
News Conference News ESC 2023 ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More Michael O'Riordan September 06, 2023
News Conference News ESC 2023 New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground Caitlin E. Cox August 30, 2023
News Conference News ESC 2022 Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE Michael O'Riordan August 31, 2022
News Conference News ESC 2022 Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration Michael O'Riordan August 29, 2022
News Conference News ESC 2022 Polypill Bests Usual Care in Patients With Recent MI: SECURE Michael O'Riordan August 26, 2022
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Conference News ESC 2021 Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention Michael O'Riordan August 31, 2021
News Conference News ESC 2019 CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients Shelley Wood September 03, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Conference News ESC 2017 Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1 Michael O'Riordan September 05, 2017
Presentation ESC 2017 Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China Presenter: Anselm K. Gitt August 30, 2017
Presentation ESC 2017 Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial Presenter: Robert Giugliano August 28, 2017
News Conference News ESC 2017 Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab Michael O'Riordan August 28, 2017
News Conference News ESC 2016 Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD Todd Neale September 09, 2016
News Conference News ESC 2016 When Unblinded to Statin Therapy, Patients’ Muscle-Related Adverse Events Shoot Up: ASCOT Analysis Michael O'Riordan August 31, 2016
News Conference News ESC 2016 Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER Michael O'Riordan August 30, 2016
News Conference News ESC 2016 Long-term Exposure to Lower LDL Cholesterol, Blood Pressure Has Potential to Dramatically Cut CV Risk Todd Neale August 29, 2016